Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

• Status: Completed
• Trial end date: 2020-08-25
• Target enrollment: 0
• Participant gender: Male

Summary

The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Thomas Hope; University of California, San Francisco
• Treatments: Edetic Acid

Criteria

Inclusion Criteria:

1. Male, age >= 18.

2. Histopathologically proven prostate adenocarcinoma.

3. Concern for metastatic disease in one of the following settings:

1. Initial staging with intermediate to high risk prostate cancer.

2. Biochemical recurrence after initial therapy.

4. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

1. Patient unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.